NCT04452591Phase 3Active not recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2030-06-16Estimated

Enrollment · participants190Estimated

Source updated2026-07-10Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-16 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2027-12-24

+ Updated value

2030-06-16

Check registry source

Study details

Conditions studied

Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer

Treatments or interventions studied

Cretostimogene GrenadenorepvecBiological

Primary outcomes · main study measures

Read the study measures

measure: Cohort C:; description: To determine the Complete Response rate at any time in patients with BCG-unresponsive CIS with or without concomitant HG Ta/T1 papillary disease.; timeFrame: 36 months; measure: Cohort P:; description: To determine the high-grade EFS of cretostimogene in patients with BCG-unresponsive HG Ta/T1 papillary disease without CIS.Ta/T1 papillary disease without CIS.; timeFrame: 36 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history